NL-OMON34887已完成2 期
A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy - Compare AUY922 with docetaxel or irinotecan in gastric cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Patients with cytological or histological confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
- •- Patients with progressive disease (radiological confirmed) after one line of chemotherapy for advanced gastric cancer.
- •- At least one measurable lesion as defined by RECIST.
- •- Patients who meet the following criteria will be eligible for PET assessments:
- •o At least one lesion must be measurable ( >2cm)
- •o Able to lie still and flat on the PET table.
- •- WHO Performance Status of < 1
- •- Life expectancy of > 12 weeks
- •- Patients must have the following laboratory values:
- •o Absolute Neutrophil Count *1.5x109/L
- •o Hemoglobin * 9 g/dl <= 5.58 mmol/l
- •o Platelets *100x109/L
- •o Potassium, total calcium (corrected for serum albumin) and phosphorus within normal limits
- •o Magnesium above LLN
- •o Adequate liver function defined as:
- •AST/SGOT and ALT/SGPT * 1.5 x Upper Limit of Normal if Alkaline Phosphatase > 2.5 ULN or
- •AST/SGOT and ALT/SGPT * 2.5 x Upper Limit of Normal (ULN) if Alkaline Phopaphatse * 5.0 x ULN if liver metastases are present
- •o Serum bilirubin * 1.5 x ULN
- •o Serum creatinine * 1.5 x ULN or 24-hour clearance * 50 ml/min.
- •o Negative serum pregnancy test.
排除标准
- •- Patients with CNS metastasis which are symptomatic or require treatment for symptom control and/or gowing.
- •- Prior treatment with any HSP90 or HDAC inhibitor
- •- Systemic anti-cancer treatment prior to the first dose of studymedication within the following timeframes:
- •o Radiotherapy, conventional chemotherapy and monoclonal antibodies, such as trastuzumab: within 4 weeks
- •o Palliative radiotherapy: within 2 weeks
- •o Nitrosoureas, mitomycin: within 6 weeks
- •o Any continuous-dosing of systemic anti-cancer therapiefor which the recovery period is not known, or investigational drugs within a duration of * 5 half lives of the agent and their active metabolites (if any)
- •- Treatment with therapeutic doses of coumarin-type anticoagulants. Maximum daily dose of 2mg allowed.
- •- Known sensitivity to taxanes, drugs formulated with polusorbate 80 or patients with Acute Myeloid Leukemia.
- •- Concomitant use of agents that induce, inhibit or are metabolized by CYP3A4, neuromuscular blocking agenst and Atazanavir sulfate.
- •- Unresolved diarrhea * CTCAE grade 1
- •- Patients with malignant ascites that requires invasive treatment.
- •- No archival tumor sample available or unwilling to have a fresh tumor sample collected at baseline.
- •- Acute or chronic liver or renal disease.
- •- Other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol.
- •- Impaired cardiac function, including any one of the following:
- •o History (or family history) of long QT syndrome.
- •o QTc * 450 msec on screening ECG.
- •o Clinically manifested ischemic heart disease * 6 months prior to study start.
- •o History of heart failure or left ventricular (LV) dysfunction (LVEF * 45%) by MUGA or ECHO.
- •o Clinically significant ECG abnormalities.
- •o History or presence of atrial fibrillation, atrial flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de Pointes.
- •o Other clinically significant heart disease (e.g congestive heart failure, uncontrolled hypertension)
- •o Clinically significant resting bradycardia (< 50 beats per minute).
- •o Treatment with any medication which has a relative risk of prolonging the QTcF interval or inducing Torsades de Pointes.
- •o Cardiac pacemaker
- •- Known diagnosis of HIV infection
- •- history of another primary malignancy that is currently clinically significant or currently requires active intervention.
研究者
相似试验
进行中（未招募）
不适用
A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapyPatients with advanced gastric cancer who have progressed after one line of chemotherapyMedDRA version: 12.1Level: PTClassification code 10017758Term: Gastric cancerEUCTR2009-015407-47-NLovartis Pharma Services AG120
进行中（未招募）
不适用
A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy. - NDEUCTR2009-015407-47-ITOVARTIS FARMA120
进行中（未招募）
不适用
a clinical study comparing the efficacy and safety of AUY922, aninvestigational compound, to standard treatments in patients withadvanced gastric cancerPatients with advanced gastric cancer who have progressed after one line of chemotherapyMedDRA version: 13.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015407-47-DEovartis Pharma Services AG120
进行中（未招募）
1 期
a clinical study comparing the efficacy and safety of AUY922, an investigational compound, to standard treatments in patients with advanced gastric cancerPatients with advanced gastric cancer who have progressed after one line of chemotherapyMedDRA version: 13.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015407-47-GBovartis Pharma Services AG
进行中（未招募）
1 期
Optimal scheme of administration of pazopanib in thyroid carcinomaIodine refractory Differentiated Thyroid CarcinomaMedDRA version: 14.1 Level: LLT Classification code 10043702 Term: Thyroid carcinoma System Organ Class: 100000004864EUCTR2012-003162-41-FRCentre Léon Bérard168